Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

• Published in: BMC cancer Vol. 22; no. 1; pp. 1 - 10
• Main Authors: Rohaan, Maartje W., Stahlie, Emma H. A., Franke, Viola, Zijlker, Lisanne P., Wilgenhof, Sofie, van der Noort, Vincent, van Akkooi, Alexander C. J., Haanen, John B. A. G.
• Format: Journal Article
• Language: English
• Published: London BioMed Central 04.08.2022; BMC
• Subjects: Cancer therapies; Clinical trials; Combination therapy; Disease; Early metastatic; Herpes simplex; Immune checkpoint inhibitor; Immune checkpoint inhibitors; Immune response; Immunotherapy; Lymphocytes; Medical prognosis; Melanoma; Metastases; Metastasis; Monoclonal antibodies; Neoadjuvant; Nivolumab; Patients; PD-1 protein; Quality of life; Response rates; Seroconversion; Study Protocol; Surgery; Talimogene laherparepvec; Targeted cancer therapy; Toxicity; Tumors; Vaccines; Netherlands

Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for patients wi...